Overall, these preliminary data could represent the starting point for the development of clinical trials using anti-CD38 antibodies alone or in combination with anti-PD-1 for the treatment of the small subgroup of SS patients who express CD38 and would likely benefit from such targeted therapy. This evidence concerns the gene CD38 and synovial sarcoma.